Drugs / M8891
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03138538 | Aug 2017 → Sep 2020 | renal cell carcinoma | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M8891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03138538 ↗ |
| Action | Inhibit | “M8891 is a selective and reversible inhibitor of methionine aminopeptidase 2 (MetAP2).” PMID 37798538 ↗ Oct 2023 |
| Route | Oral | “Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression,...” NCT03138538 ↗ |
| Target | METAP2 | “M8891 is a selective and reversible inhibitor of methionine aminopeptidase 2 (MetAP2).” PMID 37798538 ↗ Oct 2023 |